Abstract
We conducted a phase I clinical trial of the live-attenuated recombinant human parainfluenza virus type 2 (HPIV2) vaccine candidate rHPIV2-15C/948L/∆1724 sequentially in adults, HPIV2-seropositive children, and HPIV2-seronegative children, the target population for vaccination. rHPIV2-15C/948L/∆1724 was appropriately restricted in replication in adults and HPIV2-seropositive children but was overattenuated for HPIV2-seronegative children.
Author supplied keywords
Cite
CITATION STYLE
Karron, R. A., Herbert, K., Wanionek, K., Schmidt, A. C., Schaap-Nutt, A., Collins, P. L., & Buchholz, U. J. (2023). Evaluation of a Live-Attenuated Human Parainfluenza Virus Type 2 Vaccine in Adults and Children. Journal of the Pediatric Infectious Diseases Society, 12(3), 173–176. https://doi.org/10.1093/jpids/piac137
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
